The IBRI fills a major research gap by connecting academic discovery and industry development, and public and private enterprise to improve human health.

What

  • The Indiana Biosciences Research Institute (IBRI) is an independent, nonprofit discovery science and applied research institute currently targeting diabetes, metabolic disease, poor nutrition and related health data science. Inspired by Indiana’s leading life sciences companies, research universities and philanthropic community, the IBRI is building a world-class organization of researchers, innovators and entrepreneurs to catalyze scientific discovery and its application, resulting in improved health outcomes for Indiana patients and beyond.

  • Founders of the IBRI were Lilly Endowment, the state of Indiana, Eli Lilly and Company Foundation, Roche Diagnostics, Dow AgroSciences (now Corteva Agriscience), Eli Lilly and Company, Indiana University Health, Cook Medical, Indiana University School of Medicine, BioCrossroads and the city of Indianapolis.

Why

  • Indiana’s life sciences economy comprises 1,751 companies employing 56,000 with $97,000+ annual salaries and has a $79 billion annual economic impact to the state.
  • In 2012, Indiana state, civic, corporate and academic leaders called for creating an independent applied research institute to serve as a novel, mutually beneficial bridge between industry and academia. The goal is to capture and accelerate game-changing, outcome-driven research—both industry-sponsored and publicly funded—through the attraction and retention of world-class talent to the IBRI.
  • The IBRI exists to bring together companies and universities to work collaboratively on interrelated health issues that are of both global significance and have a disproportionate impact on Hoosiers—diabetes, metabolic disease and poor nutrition.

Where

  • The IBRI’s labs and offices are currently housed in approximately 20,000-square feet of leased space in the Indiana University School of Medicine’s Biotechnology Research and Training Center (BRTC) at 1345 W. 16th Street on Indianapolis’ near-westside on the border of the planned 16 Tech Innovation District.
  • With groundbreaking in late 2018, the IBRI will anchor 68,000 square feet of the new Advanced Research and Innovation Building in 16 Tech with office, innovation, collaboration and lab space. Completion is scheduled for mid-2020. 

Who

  • The IBRI employs 39 full-time scientific and administrative employees, and up to a dozen students and interns for its research teams.
  • The IBRI's leadership includes:
    • Mark Andersen, CPA, CFA, Chief Financial Officer, Vice President of Administration
    • Robert Considine, PhD, Professor of Medicine, Director, the Diabetes Center
    • Decio Eizirik, MD, PhD, Research Fellow, IBRI Diabetes Center
    • Rainer Fischer, PhD, Senior Executive for Innovation and Discovery
    • Stephanie Grinage, MHA, Vice President for Advancement
    • Steven Haney, PhD, Research Fellow, Pharmaceutical Biotechnology Center
    • Teresa Mastracci, PhD, Senior Scientist, IBRI Diabetes Center
    • Jay McGill, PhD, Chief Operating Officer
    • Michael Pugia, PhD, Research Fellow, Bioanalytical Technologies
    • Daniel Robertson, PhD, Research Fellow, Director, Applied Data Sciences Center
    • Victor Wroblewski, PhD, Research Fellow, Pharmaceutical Biotechnology Center
    • Vidadi Yusibov, PhD, Senior Research Fellow, Director, Pharmaceutical Biotechnology Center

When

  • The IBRI's goal over the next five years is to attract new and retaining existing talent to build a world-class organization of researchers, innovators and entrepreneurs who will catalyze scientific discovery and its application, resulting in improved health and nutrition outcomes for patients in Indiana and around the world.

How

  • The IBRI was initially funded with $50 million provided by the state of Indiana, Lilly Endowment, Eli Lilly and Company, Roche Diagnostics, Dow AgroSciences, IU Health and Indiana University. In 2016, the institute received an additional $88.5 million in funding commitments from Lilly Endowment, Eli Lilly and Company Foundation and Cook Medical. In 2017 the institute received an additional $20 million commitment from the state of Indiana.
  • The IBRI is looking to expand its partnerships with life sciences and IT companies and philanthropic organizations, and individual donors, worldwide to increase the potential for research, discovery, translation and collaboration. For more information about donation and philanthropic opportunities, please visit http://www.indianabiosciences.org/giving/ 

The IBRI’s Mission, Vision, Values

  • MISSION: To become the leading independent, industry-inspired applied research institute in the discovery and development of innovative solutions to improve health, targeting diabetes, metabolic disease and poor nutrition.
  • VISION: Build a world-class organization that catalyzes activities across Indiana’s life sciences community and beyond.
  • VALUES:

    Collaborative – We cannot do research alone; this is a team sport and a long game; the IBRI exists to enhance the robust life sciences ecosystem by bridging industry and academic research.
    Teamwork – We work together as one team, both within and across our operations, and externally with our partners and stakeholders.
    Innovative – We are focused on game-changing research to help solve the most persistent health problems and challenges.
    Integrity – We do the right thing by adhering to the highest ethical standards and being honest, respectful, transparent, responsible, and accountable.
    Inclusive – We operate in a diverse ecosystem of colleagues, partners, stakeholders, and patients where we respect diversity in people and in ideas.

The IBRI’s Research Areas

The IBRI is focused on discovery and applied research to facilitate the development of technologies and innovations aimed at improving human and animal health, agriculture and the environment.

  • The IBRI Diabetes Center (IDC)
    Dr. Considine and his team are studying the molecular basis of diabetes and its complications. In one focus area, Dr. Mastracci’s lab is using zebrafish, mice and human tissue to explore mechanisms for beta cell regeneration. This center is actively recruiting diabetes investigators to the Lilly Diabetes Center of Excellence at the IBRI. The LDCE was integrated into the IDC in the fall of 2018 as a talent and funding collaboration with Eli Lilly and Company and Indiana University School of Medicine to expand diabetes research at the IBRI.
  • The Applied Data Sciences Center (ADSC)
    Dr. Robertson and his team are making vast amounts of health data accessible for analysis by industry and academic partners to better identify and predict human diseases.
  • The Pharmaceutical Biotechnology Center (PBC)
    Dr. Yusibov and the team he is assembling will focus on human health concerns through the development and manufacturing of therapeutic antibodies and vaccines. The center has interdisciplinary science teams working together on a common goal. The PBC also has access to Eli Lilly and Company's Fab Phage Display Library to enhance the discovery of therapeutic antibodies.

Governance

  • The Board of Directors supervises the IBRI management structure. Members include a representative of the state of Indiana, the CEO of the IBRI, and other high-level members representing the life sciences industry, research institutions and state universities.
  • The IBRI's Scientific Advisory Board provides guidance on the direction and implementation of research and development.

Contact
IBRI
Office: 317-983-3350
media@indianabiosciences.org